Analysts See $-2.04 EPS for Sage Therapeutics, Inc. (SAGE)

February 14, 2018 - By Louis Casey

 Analysts See $ 2.04 EPS for Sage Therapeutics, Inc. (SAGE)
Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.23, from 0.98 in 2017Q2. It increased, as 33 investors sold Sage Therapeutics, Inc. shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported.
Balyasny Asset Mngmt Ltd Liability accumulated 359,802 shares. Emerald Mutual Fund Advisers Tru owns 62,708 shares. Bnp Paribas Arbitrage, New York-based fund reported 6,922 shares. Cutter Brokerage Inc holds 0.13% or 5,226 shares. Rhenman Prns Asset Management holds 0.4% or 50,000 shares. Jane Street Grp Inc Llc holds 13,118 shares. Lord Abbett Ltd Liability Corporation, New Jersey-based fund reported 275,665 shares. Td Asset Mgmt has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Goldman Sachs Gp Incorporated owns 338,078 shares or 0.01% of their US portfolio. Fred Alger Management Inc reported 10,009 shares. Hershey stated it has 1,887 shares or 0% of all its holdings. Strs Ohio reported 69,900 shares or 0.02% of all its holdings. State Board Of Administration Of Florida Retirement System reported 16,852 shares stake. Barclays Public Limited has invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Guggenheim Cap Lc has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 84,088 shares.

Since December 14, 2017, it had 0 buys, and 2 selling transactions for $17.36 million activity. Another trade for 60,000 shares valued at $9.57M was sold by Robichaud Albert.

Analysts expect Sage Therapeutics, Inc. (NASDAQ:SAGE) to report $-2.04 EPS on February, 22.They anticipate $0.54 EPS change or 36.00 % from last quarter’s $-1.5 EPS. After having $-1.97 EPS previously, Sage Therapeutics, Inc.’s analysts see 3.55 % EPS growth. The stock increased 0.48% or $0.76 during the last trading session, reaching $160.1. About 1.06 million shares traded or 14.90% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. The company was maintained on Thursday, December 7 by Cowen & Co. Raymond James upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Wednesday, December 14. Raymond James has “Strong Buy” rating and $84 target. BMO Capital Markets maintained it with “Buy” rating and $8400 target in Thursday, August 3 report. As per Tuesday, September 12, the company rating was maintained by Needham. BMO Capital Markets maintained the shares of SAGE in report on Thursday, November 9 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Bank of America on Thursday, November 16. H.C. Wainwright initiated Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, June 23. H.C. Wainwright has “Buy” rating and $56 target. As per Tuesday, September 5, the company rating was maintained by Cowen & Co. The firm has “Buy” rating by Leerink Swann given on Thursday, December 7. BMO Capital Markets maintained it with “Buy” rating and $203.0 target in Wednesday, January 31 report.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.29 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

More recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: which released: “Stock Review for Biotech’s Investors — Sage Therapeutics, Sarepta …” on February 12, 2018. Also published the news titled: “Sage Therapeutics Reaches Analyst Target Price” on January 24, 2018.‘s news article titled: “Commit To Buy Sage Therapeutics At $130, Earn 13.4% Using Options” with publication date: January 31, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: